NCT02829983

Brief Summary

To assess the periodontal clinical response and the possible adverse effects of the clarithromycin combined to periodontal mechanical therapy in the treatment of patients with generalized aggressive periodontitis.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2014

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2014

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2015

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2015

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

July 8, 2016

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 12, 2016

Completed
1.3 years until next milestone

Results Posted

Study results publicly available

October 17, 2017

Completed
Last Updated

November 21, 2017

Status Verified

October 1, 2017

Enrollment Period

1.4 years

First QC Date

July 8, 2016

Results QC Date

May 9, 2017

Last Update Submit

October 18, 2017

Conditions

Keywords

clarithromycinperiodontal debridementaggressive periodontitis

Outcome Measures

Primary Outcomes (1)

  • Clinical Attachment Level

    Distance from bottom of pocket to the cement-enamel junction (CEJ).

    6 months

Secondary Outcomes (1)

  • Probing Depth

    6 months

Study Arms (2)

clarithromycin group

ACTIVE COMPARATOR

20 subjects that received one-stage full-mouth ultrasonic debridement (FMUD) associated with clarithromycin (500 mg - 12/12 hours) for 3 days.

Drug: ClarithromycinOther: One-stage full-mouth ultrasonic debridement (FMUD)

placebo group

PLACEBO COMPARATOR

20 subjects that received FMUD associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).

Drug: PlaceboOther: One-stage full-mouth ultrasonic debridement (FMUD)

Interventions

Use of 500mg of Clarithromycin twice a day for 3 days

Also known as: macrolide
clarithromycin group

Use of placebo tablets twice a day for 3 days.

placebo group

One session of Periodontal debridement using ultrasonic device.

clarithromycin groupplacebo group

Eligibility Criteria

Age18 Years - 35 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • diagnosis of Generalized Aggressive Periodontitis
  • presence of ≥20 teeth
  • presence of ≥ 6 sites presenting probing depth (PD) ≥5mm with bleeding on probing (BOP) and ≥2 sites with PD ≥7mm (including incisors and first molars, in addition to two other non-contiguous teeth between them)
  • good general health
  • \<35 years of age
  • agree to participate in the study and sign a written consent

You may not qualify if:

  • pregnant or lactating
  • suffering from any other systemic disease (e.g. cardiovascular, diabetes, blood dyscrasias, immunodeficiency, etc) which could alter the course of periodontal disease
  • received antimicrobials in the previous 6 months
  • taking long-term anti-inflammatory drugs
  • received a course of periodontal treatment within the last 12 months
  • smoked

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (4)

  • Casarin RC, Peloso Ribeiro ED, Sallum EA, Nociti FH Jr, Goncalves RB, Casati MZ. The combination of amoxicillin and metronidazole improves clinical and microbiologic results of one-stage, full-mouth, ultrasonic debridement in aggressive periodontitis treatment. J Periodontol. 2012 Aug;83(8):988-98. doi: 10.1902/jop.2012.110513. Epub 2012 Jan 30.

  • Hammami C, Nasri W. Antibiotics in the Treatment of Periodontitis: A Systematic Review of the Literature. Int J Dent. 2021 Nov 8;2021:6846074. doi: 10.1155/2021/6846074. eCollection 2021.

  • Khattri S, Kumbargere Nagraj S, Arora A, Eachempati P, Kusum CK, Bhat KG, Johnson TM, Lodi G. Adjunctive systemic antimicrobials for the non-surgical treatment of periodontitis. Cochrane Database Syst Rev. 2020 Nov 16;11(11):CD012568. doi: 10.1002/14651858.CD012568.pub2.

  • Andere NMRB, Castro Dos Santos NC, Araujo CF, Mathias IF, Taiete T, Casarin RCV, Jardini MAN, Shaddox LM, Santamaria MP. Clarithromycin as an Adjunct to One-Stage Full-Mouth Ultrasonic Periodontal Debridement in Generalized Aggressive Periodontitis: A Randomized Controlled Clinical Trial. J Periodontol. 2017 Dec;88(12):1244-1252. doi: 10.1902/jop.2017.170165. Epub 2017 Jul 3.

MeSH Terms

Conditions

Aggressive Periodontitis

Interventions

ClarithromycinMacrolides

Condition Hierarchy (Ancestors)

PeriodontitisPeriodontal DiseasesMouth DiseasesStomatognathic Diseases

Intervention Hierarchy (Ancestors)

ErythromycinPolyketidesLactonesOrganic ChemicalsMacrocyclic CompoundsPolycyclic Compounds

Results Point of Contact

Title
Mauro Pedrine Santamaria
Organization
Universidade Estadual Paulista Júlio de Mesquita Filho

Study Officials

  • Mauro P Santamaria, DDS, PhD

    UPECLIN HC FM Botucatu Unesp

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
DDS,MS,PhD

Study Record Dates

First Submitted

July 8, 2016

First Posted

July 12, 2016

Study Start

March 1, 2014

Primary Completion

August 1, 2015

Study Completion

November 1, 2015

Last Updated

November 21, 2017

Results First Posted

October 17, 2017

Record last verified: 2017-10